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Abstract: To investigate the prognostic significance of Survivin and Nectin-4 expression in breast carcinomas.
Imprint smears were obtained from 140 breast carcinoma specimens and studied immunocytochemically for the
expression of Survivin and Nectin-4. The results were correlated with several clinicopathological parameters,
including five-year survival. Increased Survivin staining pattern correlated with increased grade (p < 0.0001),
increased lymph node invasion (p < 0.0001), increased tumor size and reduced survival (p < 0.0001). Elevat-
ed Nectin-4 expression also correlated significantly with increased grade (p < 0.0001), increased tumor size
(p < 0.0001) and reduced survival (p < 0.0001). In addition, Survivin and Nectin-4 staining patterns correlated
strongly with one another (p < 0.0001). However, on multivariate analysis, neither Survivin nor Nectin-4 expres-
sion seemed to have an independent impact on survival in our study cases. The findings of our study suggest that
increased expression of Survivin and Nectin-4 may indicate a worse prognosis in breast cancer patients. The
exact implications of the expression of these markers in breast cancer prognosis and treatment remain to be
clarified. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 1, pp. 26–33)
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Introduction
Breast cancer is a complex and heterogeneous di-
sease at the molecular level. Therefore the emer-
ging molecular classification of breast cancer is
based on data obtained from gene and protein ex-
pression profiling.
Immunohistochemistry has helped in defining the
molecular and prognostic signatures of breast can-
cer. Identifying new protein markers that help im-
prove patient management is a priority in breast can-
cer research [1–6].
Survivin has been identified as a novel inhibitor
of apoptosis. It blocks common downstream ele-
ments of both the mitochondrial pathway and the
death receptor pathway, by directly inhibiting ter-
minal effectors caspases activity [7–10].
Survivin is expressed during embryonic and fe-
tal development, but is undetectable in terminally
differentiated normal adult tissue. However, it is
re-expressed in human cancer cells at a frequency
of 34–100% [11–13]. As a prognostic factor, Sur-
vivin expression is significantly associated with
a poor clinical outcome in cancers including breast
cancer [8, 14–18].
Nectins are cell adhesion molecules involved in
the regulation of epithelial physiology. Four Nectins
have been described so far. Nectin-4 is a new tumor-
-associated antigen and a reliable marker for breast
carcinoma. Furthermore, it represents a sensitive and
complementary marker for the follow-up of patients
with metastatic breast carcinoma [19–21].
Our aim was to study the expression pattern of
Survivin and Nectin-4 proteins in imprints of inva-
sive breast carcinoma and their clinicopathological
and prognostic value, as well as their relation to mar-
kers indicative of the tumor phenotype.
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Material and methods
One hundred and forty breast tumors, freshly resec-
ted from women who had undergone total mastec-
tomy, were studied. Cytologic imprint smears were
obtained by touching the cut surface of breast carci-
noma tissues. One hundred and fifteen of the tumors
were histologically ductal invasive of no special type,
and 25 were lobular invasive carcinomas. The pa-
tients were aged from 28 to 85 years with a mean of
55.72 years. The histological diagnosis was deter-
mined during routine pathological assessment. The
tumors were classified according to the histologi-
cal typing of breast tumors by the WHO [22] and
the tumors were graded according to the Scarff-
Bloom Richardson classification as modified by El-
ston and Ellis [23]. Staging at the time of diagnosis
was based on the TNM system [24]. Tumor size (less
than 2 cm, 2 to 5 cm, more than 5 cm) and lymph
node status were evaluated separately. Additional
information was recorded concerning the patient’s
menopausal status (ERa/PR) as determined immu-
nohistochemically [23] and HER-2 expression. The
clinicopathological characteristics of the patients
are listed in Table 1. Follow-up was available for
all 140 patients every three months post-operative-
ly. The follow-up period was 60 months. At the end
of those 60 months, 32 (22.9%) patients had died of
their disease and 108 patients had developed recur-
rence. Mean survival time was 36.71 months (range
5 to 60 months) and median survival time was 37.50
months. Patient outcome was defined as disease
overall survival.
None of the patients had received radiation or
chemotherapy preoperatively. After surgery, the pa-
tients received adjuvant therapy, depending on the
extent of the disease, including anti-estrogen therapy
and radiation therapy when indicated. Premenopausal
patients with lymph nodes involvement were treated
with four cycles of adjuvant chemotherapy using dox-
orubicin/cyclophosphamide followed by paclitaxel for
four cycles.
Imprint smears were obtained from each patient
by touching the cut surface of the freshly resected
tumor tissues. We prefer to use imprint smears in-
stead of paraffin-embedded tissue sections and cells
(cell blocks), because the latter present difficulties
with regard to immunoreactivity. Depending on the
thickness of the section, there will always be a num-
ber of cells either sliced or overlapped, leading eit-
her to false low or to false high immunoreactivity,
respectively [25–27]. Furthermore, tissue fixation
and, to a lesser degree, tissue processing, are po-
tential causes of variation in the reproducibility of
immunohistochemical staining [28]. Above and be-
yond that, in cytologic preparations, the cells are
whole, a larger surface of the tumor is sampled, and
tissue is preserved for subsequent pathological and
molecular analyses [27, 29–31]. It is now firmly es-
tablished that a wide variety of markers can be ap-
plied on cytologic preparations and that immuno-
cytochemistry correlates well with immunohisto-
chemistry [32–36].
For immunocytochemistry 4 smears were fixed for
10 minutes in 5% buffered formalin and stored at
–70°C until used.
Immunostaining was performed by the Avidin-
-Biotin Complex immunoperoxidase method [37].
Smears were incubated for 45 minutes with a normal
rabbit serum diluted 1:40 in PBS. Then the smears
were rinsed in three changes of PBS for five minutes
each and incubated overnight in Survivin (0–8 Santa
Cruz Biotechnology, USA) at a dilution 1:50 and
Nectin-4 antibody (AF2659 Browse by Molecule,
USA) at a dilution of 1:100. After washing in PBS,
the smears were incubated with rabbit anti-mouse
biotinylated immunoglobulins diluted 1:200 followed
by the ABC complex/HPR. Visualization was
achieved by a final incubation in 3,3'-diaminoben-
zide tetrahydrochloride. The smears were counter-
stained with Mayer’s hematoxylin. Known positive
controls were also stained simultaneously. Negative
controls were stained by omitting the primary anti-
bodies incubation.
The results were interpreted by two independent
cytologists by means of light microscopic observa-
tion. In cases where staining was heterogeneous in
the slide, examined fields included those with the
highest and those with the lowest percentage of
stained cells. The score was the average of ten dis-
tinct high power fields observed at × 400 magnifi-
cation. Nuclear or cytoplasmic staining for Survivin
and cytoplasmic staining for Nectin-4 were scored
on a scale of zero to three, as follows: a score of 0
was given when there was no staining; a score of 1 if
there was staining in less than 10% of cells; a score
of 2 if there was moderate to strong staining in
11–50% of cells and a score of 3 if strong staining
was detected in more than 50% of cells. For the pur-
poses of statistical analysis, scores of 1, 2 and 3 were
considered positive, and a score of 0 was considered
negative (Figures 1, 2).
Statistical analysis of the results was performed
using Pearson’s c2 test. Survival curves were construc-
ted with the use of the Kaplan–Meier method and
compared using the log-rank test. Multivariate anal-
ysis was performed with the use of Cox’s proportion-
al hazard model.
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Results
Table 1 also provides the distribution of clinicopatho-
logical characteristics in the 140 breast tumors stu-
died. Thirty eight women were premenopausal and
102 postmenopausal. Thirty five tumors were histo-
logical grade I, 40 grade II and 65 grade III. Tumor
sizes were as follows: 37 were £ 2 cm, 78 were 2–5 cm,
and 25 were ≥ 5 cm. According to the number of pos-
itive nodes, four groups were formed (0 = 35 patients;
1–3 = 59 patients; 4–9 = 37 patients; and >10 = 9 pat-
ients) with positive lymph nodes. Of the 140 tumors,
90 (64.3%) were ER and 80 (57.1%) PR positive.
HER-2 positivity was 31.4% as determined immuno-
histochemically.
Table 2 shows the distribution of Survivin and
Nectin-4 staining pattern in all cases of breast carci-
nomas. Survivin was expressed in 65.7% and Nectin-4
in 64.3% of all tumors.
Survivin immunoreactivity was observed both in
the cytoplasm and nuclear compartment of malig-
nant cells or only in the cytoplasm or nucleus. Cyto-
plasmic Survivin immunoreaction was observed in
75/92 (81.5%) cases, while nuclear was observed in
26/92 (28%) cases. Twenty two (23.9%) cases showed
Figure 1. Breast adenocarcinoma cells with strong nuclear
and mild cytoplasmic expression for Survivin (magnifica-
tion × 500)
Figure 2. Clusters of breast adenocarcinoma cells with
positive membrane and cytoplasmic expression for Nectin-4
(magnification × 500)
Figure 3. Overall survival curves according to Survivin and
Nectin-4 expression
Table 1. Clinicopathological characteristics of patients
Variables Number %
Menopausal status
Premenopausal 38 27.1
Postmenopausal 102 72.9
Tumor size (cm)
< 2 37 26.4
2–5 78 55.7
> 5 25 17.9
Histological type
Ductal 115 82.1
Lobular 25 17.9
Histological grade
I 35 25.0
II 40 28.6
III 65 46.4
Lymph nodes status
0 35 25.0
1–3 59 42.1
4–9 37 26.4
≥ 10 9 6.4
ERa immunostatus
Negative 50 35.7
Positive 90 64.3
PR immunostatus
Negative 60 42.9
Positive 80 57.1
HER-2
Negative 96 68.6
Positive 44 31.4
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(p < 0.0001) as well as with a negative ERa and PR
status (p < 0.0001). Further associations were de-
monstrated between Survivin and Nectin-4 staining
respectively and the remaining clinical and patho-
logical parameters examined.
The independent relationship of Survivin and
Nectin-4 was studied with Cox multivariate regres-
sion analysis. We thus could establish whether the
prognostic value of Survivin and Nectin-4 as found
in univariate analyses could be attributed to its rela-
tionship with other clinicopathological factors, or
whether Survivin and Nectin-4 contribute indepen-
dently to prognosis. A multivariate analysis was per-
formed, including age, menopausal status, nodal sta-
tus, tumor size, histological type, ERa/PR status and
HER-2. For overall survival, age (p < 0.0001), grade
(p < 0.0001) and lymph nodes status (p < 0.014)
were significant (Table 4). Therefore, neither Sur-
vivin nor Nectin-4 expression seemed to have an in-
dependent impact on survival in our studied cases.
Discussion
Our study detected positive expression for Survivin
in 65.7% of all breast carcinoma specimens. This per-
centage is within the range of previously published
reports, in the majority of which positive Survivin ex-
pression is demonstrated with the use of immunohis-
tochemistry [8].
The sub-cellular distribution of Survivin seems
to be altered during the growth and progression of
breast carcinoma, under the influence of yet un-
known molecular mechanisms. However, the exact
prognostic and clinical implications of the immuno-
histochemical localization (nuclear or cytoplasmic)
of Survivin in different types remain controversial.
Our study found Survivin to be predominantly
detected in the cytoplasmic compartment of breast
cancer cells, confirming previous observations. For-
tugno et al. showed that cytoplasmic and nuclear Sur-
vivin are immunocytochemically different, and this
might partly explain the conflicting data on Survivin
localization in solid tumors [38].
The relationship between immunocytochemical
detected cytoplasmic and nuclear localization of Sur-
vivin has been not investigated. Although we found
no relationship between cytoplasmic and nuclear
staining, a high percentage of cases with very strong
cytoplasmic intensity also showed nuclear Survivin
immunoreaction [15, 39, 40]. In the literature, cyto-
plasmic expression of Survivin is reported to be
a poor prognostic parameter in colorectal neuro-
blastoma, squamous cell and urothelial carcinoma.
On the other hand, in studies of pancreatic, gastric,
Survivin staining both nuclear and cytoplasmic com-
partment.
There seems to be no association between cyto-
plasmic and nuclear Survivin staining. However 7/12
(58.3%) cases with very strong cytoplasmic intensity
also showed nuclear staining. This was in contrast to
only 17/63 (26.9%) cases with lighter cytoplasmic
staining (p = 0.002). We failed to find any relation-
ship between positivity rate of cytoplasmic or nuclear
staining with all clinicopathological parameters ana-
lyzed. Moreover, no relationship was observed be-
tween cytoplasmic or nuclear Survivin staining with
overall survival.
Therefore, a tumor was assessed as Survivin posi-
tive if the staining was positive cytoplasmic, or posi-
tive nuclear, or both. The results of c2 analysis of the
studied variables are summarized in Table 3.
Survivin positive staining was significantly corre-
lated with increased grade (III) (p < 0.0001), in-
creased number of lymph nodes invasion (p < 0.0001)
increased tumor size (> 2 cm), negative ERa/PR sta-
tus (p < 0.0001 respectively) and positive expression
of HER-2 (p < 0.0001).
Similar associations were found for Nectin-4. Pos-
itive Nectin-4 expression was significantly associated
with increased grade (II and III) (p < 0.0001), in-
creased tumor size (p < 0.0001), negative ERa and
PR status (p < 0.0001) as well as with positive HER-2
expression (p < 0.0001).
In addition, Survivin and Nectin-4 staining patterns
correlated strongly to one another (p < 0.0001).
We evaluated the association between Survivin
and Nectin-4 expression and overall survival (Fig-
ure 3). Positive staining for Survivin and Nectin-4
was associated with lower five-year survival rates
compared to negative staining (6.5% vs. 54.2% and
3.3% vs. 58.0%) (p < 0.0001). A shorter survival was
also strongly associated with higher grade of the tu-
mor (p < 0.0001), increased number of lymph nodes
invasion (p < 0.0001), positive expression of HER-2
(p < 0.0001), and increased size of the tumor > 2 cm
Table 2. Distribution of Survivin and Nectin-4 staining
expression in 140 tumors of breast carcinoma
Staining pattern Frequency (No) Percentage (%)
Survivin
Negative 48 34.3
Positive 92 65.7
Nectin-4
Negative 50 35.7
Positive 90 64.3
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urothelial and esophageal carcinomas, no associa-
tion has been found between cytoplasmic Survivin
and patient survival [7, 9, 41, 42].
The differential nuclear and cytoplasmic localiza-
tion of Survivin is shown to be due to differences in
the amino-acid sequence of its carboxy-terminal do-
Table 4. Cox’s regression analysis of the prognostic value of the assessed variables with regard to overall survival
Variables in the equation
B SE Wald df p Exp (B)                       95% CI for Exp (B)
Lower Upper
Age 1.051 247 18.064 1 0.0001 2.861 1.762 4.646
Hist grade 1.570 0.262 35.938 1 0.0001 4.806 2.876 8.029
LN status 0.519 0.210 6.096 1 0.014 1.681 1.113 2.538
SE — standard error; B — coefficient
Table 3. Results of c2 analysis showing the correlations between Survivin and Nectin-4 staining patterns and several
clinicopathological parameters in 140 patients with breast carcinoma
Variable                       Total Staining pattern
                                        Survivin p                                  Nectin-4 p
(–) (+) (–) (+)
Histology 140
Ductal 41 (25.7%) 74 (64.3%) 0.465 42 (36.5%) 73 (63.5%) 0.669
Lobular 7 (28.0%) 18 (72.0%) 8 (32.0%) 17 (68.0%)
Grade 140
I 27 (77.1%) 8 (22.9%) < 0.0001 33 (94.3%) 2 (5.7%) < 0.0001
II 20 (50.0%) 20 (50.0%) 16 (40.0%) 24 (60.0%)
III 1 (1.5%) 64 (98.5%) 1 (1.5%) 64 (98.5%)
Tumor size [cm] 140
< 2 27 (73.0%) 10 (27.0%) < 0.0001 28 (75.7%) 9 (24.3%) < 0.0001
2–5 21 (26.9%) 57 (73.1%) 22 (28.2%) 56 (71.8%)
> 5 0 (0%) 25 (100%) 0 (0%) 25 (100%)
Lymph nodes status 140
0 27 (77.1%) 8 (22.9%) < 0.0001 33 (94.3%) 2 (5.7%) < 0.0001
1–3 20 (33.9%) 39 (66.1%) 17 (28.8%) 42 (71.2%)
4–9 1 (2.7%) 36 (97.3%) 0 (0%) 37 (100%)
> 10 0 (0%) 9 (100%) 0 (0%) 9 (100%)
ERa status 140
Negative 2 (4.0%) 48 (96.0%) < 0.0001 7 (14.0%) 43 (86.0%) < 0.0001
Positive 46 (51.1%) 44 (48.9%) 43 (47.8%) 47 (52.2%)
PR status 140
Negative 2 (3.7%) 58 (96.7%) < 0.0001 9 (15.0%) 51 (85.0%) < 0.0001
Positive 46 (57.5%) 34 (42.5%) 41 (51.3%) 39 (48.8%)
HER-2 140
Expression
Negative 48 (50.0%) 48 (50.0%) < 0.0001 47 (49.0%) 49 (51.0%) < 0.0001
Positive 0 (0%) 44 (100%) 3 (6.8%) 41 (93.2%)
Menopausal status 140
Premenopausal 13 (34.2%) 25 (65.8%) < 0.991 17 (44.7%) 21 (55.3%) 0.174
Postmenopausal 35 (34.3%) 67 (65.7%) 33 (32.4%) 69 (67.6%)
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main [43]. Moon and Tornawski suggest the cytoplas-
mic localization of Survivin in non-malignant cells
suppresses apoptosis, while its nuclear translocation
may be important in the regulation of proliferation
and differentiation [44].
In other studies of different types of cancers, the
overexpression of Survivin correlates with increased
proliferation, although the expression was cytoplas-
mic [43–46]. We believe that further studies designed
to clarify the relationship between cytoplasmic and
nuclear Survivin are needed in order to determine
the role of Survivin detected immunocytochemically
in cancer.
Our study found that Survivin positivity correla-
ted with positive expression of HER-2 and lack of PR
and ERa status. This is in agreement with other stu-
dies which have indicated that the Survivin protein
positivity detected by immunohistochemical staining
might be correlated with HER-2 expression but not
with hormone receptors [47–49].
Furthermore, Survivin staining pattern correlated
strongly with increased grade, increased tumor size,
increased number of lymph nodes involvement, and
reduced survival rates affecting the clinical outcome
but as an independent parameter. In some studies it
failed to demonstrate any association between Sur-
vivin positivity rate and the clinicopathological prog-
nostic parameters in some solid tumors [43].
The possibility that the biological role of Survivin
expression might also be influenced by tissue specific-
ity cannot be ruled out and requires further attention.
In a study by Al-Joudi et al. it was found that nega-
tive and low expression of Survivin correlated signifi-
cantly with favorable outcomes [8]. Conversely, high
expression correlated with unfavorable outcomes [8, 17].
Also, experimental studies of different kinds of
tumors have reported that overall survival is signifi-
cantly decreased in patients with neoplasms express-
ing Survivin compared to those with no expression
[41, 43, 50, 51].
Nectin-4 belongs to the family of cell adhesion
molecules that regulate the formation of adherence
functions in epithelial cells through the AF-6 afa-
din scaffold molecule [51–53]. Nectin-4 is an anti-
gen mainly expressed during embryogenesis and
highly expressed (68%) in tumors of breast origin
[20, 21]. Nectin-4 staining has been described as
prevalent cytoplasmic and discrete membrane stain
[54–56].
In the present study, we detected positive expres-
sion for Nectin-4 in 63.5% of all breast carcinoma
specimens. This percentage is within the range of pre-
viously published results [20]. Fabre Lafay et al. re-
ported positive expression of Nectin-4 in 62% of duc-
tal type and 6% of lobular type carcinomas, thus
strongly correlating with histological type. Our study
failed to reveal any difference in Nectin-4 expression
rates among histological types of breast carcinoma.
Moreover, Nectin-4 staining has been described as
prevalent in the cytoplasm and membrane of malig-
nant cells [20].
The same study found that ERa/PR negative tu-
mors expressed Nectin-4. Furthermore, serum Nec-
tin-4 is a marker of disease progression, metastatic
status and clinical outcome of patients. No correla-
tion was found between Nectin-4 and tumor size, tu-
mor grade or lymph nodes status.
Nevertheless, univariate statistical analysis of
our data showed a strong correlation between in-
creased Nectin-4 staining pattern and the follow-
ing adverse clinicopathological parameters: in-
creased grade (II, III), increased tumor size, in-
creased lymph nodes infiltration and reduced sur-
vival. These findings suggest that Nectin-4
overexpression may be a marker for a more aggres-
sive clinical behavior and worse prognosis in breast
carcinoma. However, the exact mechanism by which
Nectin-4 contributes to cancer progression remains
unclear.
We also found that the expression levels of Sur-
vivin and Nectin-4 correlated strongly to one anoth-
er. The association of Survivin and Nectin-4 with un-
favorable prognostic indicators, and with one anoth-
er, as demonstrated in our study, suggests that these
proteins may also interact in breast carcinoma in or-
der to exert their adverse effect.
In conclusion, Survivin and Nectin-4 expression
demonstrates a strong independent association with
poor prognosis. It is possible that Survivin and Nec-
tin-4 inhibitors may be of value in the treatment of
breast cancer patients. For this reason, additional
studies are needed to further define the prognostic
importance of these markers. In addition, further
molecular studies should determine the interactions
that take place between Survivin and Nectin-4 during
breast carcinogenesis, as well as their exact effect on
the clinical outcome of patients.
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